Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.

Richard MattockIlana GibbonsJoe W E MossStuart MealingNathalie LargeronStuart CarrollFabián P Alvarez

Published in: Journal of medical economics (2021)

HD TIV is cost-effective versus aTIV in people aged 65+ in England and Wales. Use of HD TIV over aTIV could increase clinical benefits and reduce the public health and economic burden of influenza.

Keyphrases

public health
high dose
low dose
stem cell transplantation